Therapeutic efficacy of an anti–IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma
Authors:
- Joe VenzorJVJoe Venzor
- Roberto BarriosRBRoberto Barrios
- Khai-Pang LeongKLKhai-Pang Leong
- David P. HustonDHDavid P. Huston
- 1 July 1999
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 104 (1) , 215-221
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Interleukin‐5 and eosinophils induce airway damage and bronchial hyperreactivity during allergic airway inflammation in BALB/c miceImmunology & Cell Biology, 1997
- Creation of a biologically active interleukin-5 monomerNature, 1996
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.Journal of Experimental Medicine, 1996
- Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.Journal of Experimental Medicine, 1996
- Enhanced detection of human IL-5 in biological fluids utilizing murine monoclonal antibodies which delineate distinct neutralizing epitopesCytokine, 1994
- Eosinophil as antigen‐presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processingEuropean Journal of Immunology, 1992
- Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic AsthmaNew England Journal of Medicine, 1992
- Eosinophilic Inflammation in AsthmaNew England Journal of Medicine, 1990
- Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor.Journal of Experimental Medicine, 1988
- Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors.Journal of Experimental Medicine, 1988